3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Carcinoma, Non-Small-Cell Lung
361
Lung Neoplasms
195
Breast Neoplasms
163
Ovarian Neoplasms
129
Triple Negative Breast Neoplasms
79
Squamous Cell Carcinoma of Head and Neck
73
Small Cell Lung Carcinoma
67
Fallopian Tube Neoplasms
56
Head and Neck Neoplasms
46
Carcinoma, Ovarian Epithelial
44
Neoplasms
40
Neoplasm Metastasis
39
Esophageal Neoplasms
36
Adenocarcinoma of Lung
36
Esophageal Squamous Cell Carcinoma
29
Prostatic Neoplasms
27
Endometrial Neoplasms
27
Uterine Cervical Neoplasms
23
Brain Neoplasms
23
Central Nervous System Neoplasms
22
Urinary Bladder Neoplasms
21
Carcinoma, Squamous Cell
21
Recurrence
20
Neuroblastoma
20
Lymphoma, Large B-Cell, Diffuse
20
Melanoma
19
Lymphoma
19
Carcinoma
19
Adenocarcinoma, Bronchiolo-Alveolar
18
Testicular Neoplasms
15
Interventions
mirvetuximab soravtansine
1
liposomal doxorubicin
1
Paclitaxel
1
Gemcitabine
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma
×
Carboplatin
×
Clear all
NCT04274426
2026-05-13
MIROVA
AGO Research GmbH
Phase 2
Active not recruiting
136 enrolled